AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18435883
Drug: Topical rifamycin
RxNorm normalized name: rifamycins Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical rifamycin
Trial: 18435883
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no rifamycin treatment)
Trial: 11525344
Drug: Preparing for
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparing for the Drug‐Free Years (PDFY) curriculum
Trial: 8806290
Drug: Co-amoxiclav suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-amoxiclav suspension (20 mg/kg amoxicillin, 5 mg/kg clavulanate potassium), orally three times a day for 14 days
Trial: 6371693
Drug: Ritodrine (max
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritodrine (max dose, 350 mcg/min intravenously for 12 hours, then 20 mg orally every 4 hours)
Trial: 6371693
Drug: Placebo (intravenously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intravenously for 12 hours, then oral therapy)
Trial: 30021759
Drug: Low phosphate
RxNorm normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low phosphate diet (regular diet plus lanthanum, 750 mg thrice/day, plus 0.7 mmol/kg body wt per day of Na as NaCl)
Trial: 24577847
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy delivered by lay providers (BLP), n = 76
Trial: 24577847
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy delivered by Ph.D.-level expert providers (PLP), n = 74
Trial: 24577847
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy delivered by lay providers (BLP)
Trial: 24577847
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy delivered by Ph.D.-level expert providers (PLP)
Trial: 22943664
Drug: Endometrial biopsy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endometrial biopsy using a pipelle curette on days 9‐12 and 21‐24 of the menstrual cycle preceding IVF treatment
Trial: 15056575
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy for command hallucinations (CTCH)
Trial: 9683362
Drug: Sucralfate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (1 g six times a day during radiotherapy)
Trial: 7530379
Drug: Risperidone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (4 mg dose in caplet form)
Trial: 7530379
Drug: Risperidone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (4 mg dose in tablet form)
Trial: 22819386
Drug: Pharmacist-initiated medication
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmacist-initiated medication reconciliation
Trial: 22819386
Drug: Physician-initiated medication
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Physician-initiated medication reconciliation
Trial: 18846487
Drug: Cruciate-sacrificing NexGen
RxNorm normalized name: Gentiana cruciata root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cruciate-sacrificing NexGen Full Flex implant
Trial: 18846487
Drug: Cruciate-retaining CKS-CC
RxNorm normalized name: Gentiana cruciata root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cruciate-retaining CKS-CC knee system
Trial: 9012115
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of iodine and selenium
Trial: 6712366
Drug: Computer-assisted (CA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-assisted (CA) initial lidocaine hydrochloride therapy
Trial: 6712366
Drug: Conventional lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional lidocaine therapy (CT)
Trial: 29884676
Drug: Concurrent changes
RxNorm normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent changes in kynurenine, quinolinic acid, 3‐hydroxyanthranilic acid, and kynurenine/tryptophan ratio
Trial: 26341357
Drug: Enhanced Behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced Behavioral Treatment (EBT)
Trial: 20378050
Drug: Active plant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active plant metabolites (e.g., flavonoids, terpenoids, glycosides) as digestive enzyme inhibitors; specific dosage and duration not available.
Trial: 20378050
Drug: Currently used
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Currently used digestive enzyme inhibitors (bacterial secondary metabolites); specific dosage and duration not available.
Trial: 8803529
Drug: Ursodiol (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodiol (600 mg)
Trial: 25083614
Drug: Single-dose rabbit
RxNorm normalized name: Rabbit
DrugBank: Rabbit (DB10415)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose rabbit antithymocyte globulin (SD-rATG) 6 mg/kg
Trial: 25083614
Drug: Divided-dose rabbit
RxNorm normalized name: Rabbit
DrugBank: Rabbit (DB10415)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divided-dose rabbit antithymocyte globulin (divided-dose-rATG)
Trial: 25083614
Drug: SD-rATG and
RxNorm normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SD-rATG and divided-dose-rATG
Trial: 18310205
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (20 ppm, weaned to 2 ppm)
Trial: 17077928
Drug: Selective head
RxNorm normalized name: Head & Shoulders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective head cooling with an insulated ice cap, aiming for a target rectal temperature of 35-35.5 degrees C and a target scalp temperature of 10-28 degrees C.
Trial: 9186381
Drug: Aspirin (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (160 mg/day) started within 48 hours of onset of suspected acute ischaemic stroke and continued for up to 4 weeks
Trial: 3880687
Drug: Labetalol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (400 mg twice a day)
Trial: 3880687
Drug: Pindolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (5 mg twice a day)
Trial: 29982097
Drug: Handgrip exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Handgrip exercise (25 repetitions, 3 times daily)
Trial: 29982097
Drug: Handgrip exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Handgrip exercise (25 repetitions, 6 times daily)
Trial: 27509600
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (acupuncture method of 'Xingnao Kaiqiao' and oral administration of nifedipine)
Trial: 23082123
Drug: Oseltamivir treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir treatment (75 mg twice a day for 5 days)
Trial: 23082123
Drug: Oseltamivir treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir treatment and prophylaxis (75 mg once a day for 10 days)
Trial: 9449256
Drug: Cefpirome (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefpirome (2 g twice daily)
Trial: 9449256
Drug: Ceftazidime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (2 g three times daily)
Trial: 25644856
Drug: Salsalate (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salsalate (4 g day(-1) for 4 weeks)
Trial: 19094160
Drug: Domperidone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone (10 mg t.i.d.) for 5 days with transdermal rotigotine patch (2 mg (24 h)(-1), 10 cm(2), total drug content 4.5 mg) applied daily for 4 days
Trial: 19094160
Drug: Transdermal rotigotine
RxNorm normalized name: rotigotine Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal rotigotine treatment (2 mg (24 h)(-1), 10 cm(2), total drug content 4.5 mg) applied daily for 4 days
Trial: 17557948
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of breast cancer-specific print materials and step pedometers
Trial: 16284984
Drug: Maintenance/consolidation chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance/consolidation chemotherapy
Trial: 12474702
Drug: Tolfenamic acid
RxNorm normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolfenamic acid 300 mg
Trial: 12474702
Drug: Pizotifen 1.5
RxNorm normalized name: Pizotifen 1.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pizotifen 1.5 mg
Trial: 28562117
Drug: Omega-3 (425
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 (425 mg/capsule, 2 capsules/day)
Trial: 28562117
Drug: Soybean isoflavones
RxNorm normalized name: Soybean isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soybean isoflavones (54.4 mg/tablet, 2 tablets/day)
Trial: 21806580
Drug: Oxygen inhalation
RxNorm normalized name: oxygen INHALATION GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen inhalation (8 L/min via face mask for 2 h)
Trial: 21885723
Drug: Oxygen inhalation
RxNorm normalized name: oxygen INHALATION GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen inhalation
Trial: 19336539
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion at 3 mg kg(‐1) h(‐1)
Trial: 19336539
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion at 6 mg kg(‐1) h(‐1)
Trial: 16927064
Drug: Glutamine supplementation
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine supplementation (0.2 g/kg per day)
Trial: 428228
Drug: Prostaglandin vaginal
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostaglandin vaginal suppositories
Trial: 31070741
Drug: Delayed Treatment
RxNorm normalized name: GRANULES, DELAYED RELEASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed Treatment control
Trial: 23605506
Drug: Fentanyl sublingual
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl sublingual spray 100 μg
Trial: 23605506
Drug: Fentanyl sublingual
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl sublingual spray 200 μg
Trial: 23605506
Drug: Fentanyl sublingual
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl sublingual spray 400 μg
Trial: 23605506
Drug: Fentanyl sublingual
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl sublingual spray 600 μg
Trial: 23605506
Drug: Fentanyl sublingual
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl sublingual spray 800 μg
Trial: 11704752
Drug: One-week application
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-week application of terbinafine cream
Trial: 11704752
Drug: Four-week application
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-week application of terbinafine cream
Trial: 31322804
Drug: Physiogel® moisturizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiogel® moisturizing creams (three test products)
Trial: 30236246
Drug: FNB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FNB with LIA of the posterior capsule
Trial: 23897949
Drug: Comprehensive rehabilitation
RxNorm normalized name: Easy Care First Aid Kit - Comprehensive KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive rehabilitation therapy
Trial: 22348643
Drug: Manual Chest
RxNorm normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manual Chest Therapy (MCT)
Trial: 16012284
Drug: Olanzapine (5‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (5‐20 mg/d)
Trial: 16012284
Drug: Haloperidol (3‐15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (3‐15 mg/d)
Trial: 16012284
Drug: Olanzapine (10‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (10‐20 mg/d)
Trial: 16012284
Drug: Risperidone (4‐12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (4‐12 mg/d)
Trial: 11789190
Drug: HANS treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HANS treatment (4 treatments of 30 min each for the first 3 days, twice a day for 3 more days, and once a day for 7 days; total 15 days)
Trial: 8861236
Drug: 27.3 mg
RxNorm normalized name: sodium fluoride 27.3 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 27.3 mg saccharin
Trial: 1623692
Drug: Verapamil (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (80 mg every 8 hours for 6 days)
Trial: 6704647
Drug: Iohexol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iohexol (40 ml, 350 mg I/ml)
Trial: 29126319
Drug: Cholecalciferol 300,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol 300,000 IU initially, then 1400 IU cholecalciferol and 500 mg of calcium daily for 150 days
Trial: 15842551
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg moxifloxacin IV as a 1 h infusion
Trial: 15842551
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg moxifloxacin IV as a 1 h infusion with oral activated charcoal (5 g before infusion, 5 g after infusion, 10 g at 2, 4, and 8 h)
Trial: 15842551
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg oral moxifloxacin with activated charcoal (10 g 15 min before and at 2, 4, and 8 h after drug administration)
Trial: 12372724
Drug: Hormonal therapies
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal therapies
Trial: 8129189
Drug: Picotamide, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Picotamide, 300 mg three times a day
Trial: 8129189
Drug: Placebo (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (three identical tablets each day)
Trial: 2782273
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS (30, 60, or 90 mg once daily)
Trial: 2782273
Drug: Sustained-release propranolol
RxNorm normalized name: propranolol Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release propranolol (80, 160, or 240 mg once daily)
Trial: 31189517
Drug: Oral semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral semaglutide (14 mg once daily for 26 weeks)
Trial: 18298423
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 0.005% ointment (FP) twice daily during the acute phase and twice weekly during the maintenance phase
Trial: 18298423
Drug: Placebo ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ointment twice weekly on consecutive days
Trial: 17889314
Drug: Bupropion +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion + nicotine patch
Trial: 15464333
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg tadalafil
Trial: 15464333
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg tadalafil
Trial: 9725545
Drug: [14C] irbesartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: [14C] irbesartan orally as a solution (50 mg)
Trial: 9725545
Drug: [14C] irbesartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: [14C] irbesartan orally as a solution (150 mg)
Trial: 9725545
Drug: Irbesartan capsule
RxNorm normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Irbesartan capsule (50 mg)
Trial: 9725545
Drug: [14C] irbesartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: [14C] irbesartan as a 30‐minute intravenous infusion (50 mg)
Trial: 8296814
Drug: Oral naproxen
RxNorm normalized name: naproxen Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral naproxen (500 mg)
Trial: 2690225
Drug: Combined modality
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined modality treatment with 2x (COPP + ABVD) followed by 20 or 40 Gy EF radiation (HD1 protocol)
Trial: 2690225
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with 3x (COPP + ABVD) followed by consolidation therapy (20 Gy IF or further chemotherapy) or salvage therapy (40Gy or 4x CEVD chemotherapy) (HD3 protocol)
Trial: 999494
Drug: Propranolol (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (20-40 mg every 4 hours, increased to 280-2320 mg per day)
Trial: 999494
Drug: Dexpropranolol (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexpropranolol (900 mg daily for 5 days)
Trial: 12384358
Drug: Pneumococcal isolates
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumococcal isolates resistant to penicillin (MIC, > or =2.0 micro g/ml)
Trial: 10063913
Drug: Bismuth subsalicylate
RxNorm normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bismuth subsalicylate (30 ml)
Trial: 10063913
Drug: Ethyl alcohol
RxNorm normalized name: Ethyl alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethyl alcohol (60 ml, 40% v/v)
Trial: 10063913
Drug: Bismuth subsalicylate
RxNorm normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bismuth subsalicylate (30 ml) pretreatment with ethyl alcohol
Trial: 28371689
Drug: Take-home self-administered
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Take-home self-administered sublingual buprenorphine-naloxone weekly (mean dose, 22.7±5.7mg)
Trial: 28371689
Drug: Take-home self-administered
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Take-home self-administered sublingual buprenorphine-naloxone weekly
Trial: 26437830
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g freeze-dried wild blueberry (WBB) powder
Trial: 26437830
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g freeze-dried wild blueberry (WBB) powder
Trial: 17923591
Drug: Combination ARB
RxNorm normalized name: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination ARB plus ACE inhibitor
Trial: 8527688
Drug: Ofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (200 mg twice daily) + Ambroxol (30 mg thrice daily)
Trial: 2109531
Drug: rIFN‐gamma at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rIFN‐gamma at 0.01 mg/m2
Trial: 2109531
Drug: rIFN‐gamma at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rIFN‐gamma at 0.1 mg/m2
Trial: 2109531
Drug: rIFN‐gamma at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rIFN‐gamma at three dose levels (0.01 mg/m2, 0.05 mg/m2, 0.1 mg/m2)
Trial: 2109531
Drug: rIFN‐gamma at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rIFN‐gamma at 0.05 mg/m2 for 6 weeks
Trial: 30312135
Drug: Fucoidan 500
RxNorm normalized name: Fucidin
DrugBank: Fusidic acid (DB02703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fucoidan 500 mg twice daily for 90 days
Trial: 30312135
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules twice daily for 90 days
Trial: 25899425
Drug: Memantine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine therapy
Trial: 21857901
Drug: DNA (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNA (4 mg i.m. by Biojector) at 0, 1 and 2 months, followed by rAd5 (10(10) PU i.m. by needle/syringe) at 6 months
Trial: 20664352
Drug: Oesomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oesomeprazole 40 mg once daily for 7 days
Trial: 7503088
Drug: Radioiodine, surgery,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioiodine, surgery, or ethanol injection for hot nodules
Trial: 2152339
Drug: Methotrexate administered
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate administered intravenously (group 2, 17 patients)
Trial: 15483371
Drug: Alcohol (0.65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.65 g alcohol/kg body weight)